Comparative Study of Autologous Blood Injection Versus Diluted Epinephrine in Treating Actively Bleeding Gastroduodenal Ulcers
Endoscopic Injection of Autologous Blood Versus Diluted Epinephrine for Control of Actively Bleeding Gastroduodenal Ulcers
1 other identifier
interventional
100
1 country
1
Brief Summary
Endoscopic injection of autologous blood can control bleeding from gastroduodenal ulcers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2012
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2012
CompletedFirst Submitted
Initial submission to the registry
March 20, 2012
CompletedFirst Posted
Study publicly available on registry
March 22, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2013
CompletedSeptember 25, 2013
September 1, 2013
1.5 years
March 20, 2012
September 24, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
hemostasis from the ulcer after injection and/or stoppage of haematemesis and melena one day after the procedure.
12 months
Secondary Outcomes (1)
development of re-bleeding after 24 hours after the procedure (occurrence of hematemesis or melena or drop of hemoglobin level >2gm/dl).
12 months
Study Arms (2)
Autologous blood
ACTIVE COMPARATORPatients will be injected by autologous blood at the edge of actively bleeding ulcer
Epinephrine injection
OTHERPatients will be injected by diluted epinephrine at the edge of actively bleeding ulcer
Interventions
10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
Eligibility Criteria
You may qualify if:
- all adult patients with gastroduodenal ulcer
You may not qualify if:
- Patients with non ulcer bleeding.
- Patients with malignancy.
- Patients with bleeding disorders or under coagulation therapy.
- Patients with known allergy to epinephrine.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zagazig University Hospitals
Zagazig, Sharqia Province, 44519, Egypt
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mohamed H Emara, MD
Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer
Study Record Dates
First Submitted
March 20, 2012
First Posted
March 22, 2012
Study Start
March 1, 2012
Primary Completion
September 1, 2013
Study Completion
September 1, 2013
Last Updated
September 25, 2013
Record last verified: 2013-09